Biomarker Analysis of HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis

Launched by AFFILIATED CANCER HOSPITAL & INSTITUTE OF GUANGZHOU MEDICAL UNIVERSITY · Dec 13, 2022

Keywords

ClinConnect Summary

To analyze the correlation between genomic alterations, gene expression characteristics and the efficacy of HIPEC combined with PD1/PDL1 inhibitor conversion therapy in patients with peritoneal metastasis of gastric cancer. Circulating tumor DNA(ctDNA) in plasma samples and DNA, RNA in tumor tissue sample were obtained over the course of HIPEC combined PD1/PDL1 inhibitor conversion treatment will be assessed by high-intensity, next-generation sequencing(NGS) to identify genomic alterations. The assay will performed used AmoyDx® Master Panel(Amoy Diagnostics Co., Xiamen, China), which contai...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Advanced gastric (gastroesophageal junction) adenocarcinoma confirmed by histology;
• • 2. Age 18-75 years, Male or Non-pregnant female
• • 3. Eastern Cooperative Oncology Group(ECOG): 0\~1；
• • 4. Negative for human epidermal growth factor receptor 2(HER-2) by immunocytochemistry or fluorescence in situ hybridization；
• • 5. The presence of gastric cancer peritoneal metastasis is confirmed by laparoscopic exploration, and the PCI≤20；
• • 6. Patients had received HIPEC combined with PD1/PDL1 inhibitor conversion therapy.
• • 7. Signed the Informed Consent Form, and blood and tissue samples can be obtained;
• Exclusion Criteria:
• • 1. Other distal metastases besides peritoneal metastases (e.g., liver, lung, pleural, brain, bone metastases, etc.);
• • 2. Other patients who were considered unsuitable for inclusion by the researchers;

Trial Officials